Live SpaceX Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow CASTLE BIOSCIENCES INC

Get SEC filing alerts via email and in your feed for CASTLE BIOSCIENCES INC

CSTL

CASTLE BIOSCIENCES INC

About CASTLE BIOSCIENCES INC

Castle Biosciences, Inc. is a molecular diagnostics company specializing in genomic and proteomic tests that aid clinicians in diagnosing and managing dermatologic cancers, Barrett’s esophagus, uveal melanoma, and mental health conditions. Its proprietary multi-analyte assays with algorithmic analysis provide personalized risk stratification to inform treatment decisions. The company serves primarily U.S. healthcare providers and relies on reimbursement from government and commercial payors to deliver clinically validated, evidence-based diagnostic solutions.
This description was generated via AI from an annual report. Updated 9 months ago.

Latest SEC Filings from CASTLE BIOSCIENCES INC

1
1
CASTLE BIOSCIENCES INC Castle Biosciences Reports $83.7 Million Revenue in Q1 2026, Net Loss Improves

Via official filing (AI summary) | about 1 month ago | 0 comments

2
1
CASTLE BIOSCIENCES INC Castle Biosciences Reports $344.2 Million Revenue for Fiscal Year 2025, Faces Net Loss

Via official filing (AI summary) | 4 months ago | 0 comments

3
1
CASTLE BIOSCIENCES INC Castle Biosciences Reports $501,000 Net Loss in Q3 2025, Revenue Decline in Dermatologic Tests

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
CASTLE BIOSCIENCES INC Castle Biosciences Reports Decline in Revenues and Significant Net Loss in Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
CASTLE BIOSCIENCES INC Castle Biosciences Reports 20.6% Revenue Growth to $87.99 Million in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
CASTLE BIOSCIENCES INC Castle Biosciences Reports 51.1% Revenue Growth to $332.1 Million in 2024

Via official filing (AI summary) | over 1 year ago | 0 comments